Skip to main content
Retour
CASBF logo

CanSino Biologics Inc.

Qualité des données : 100%
Survendu
CASBF
OTC Healthcare Drug Manufacturers - Specialty & Generic
3,86 €
0,00 € (0,00%)
Cap. Boursière : 1,35B
Fourchette du Jour
3,86 € 4,10 €
Fourchette 52 Semaines
3,20 € 6,99 €
Volume
1 200
Moyenne 50J / 200J
4,29 € / 4,91 €
Clôture Précédente
3,86 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 49,7 0,3
P/B 0,3 2,9
ROE % 0,5 3,7
Net Margin % 2,6 3,8
Rev Growth 5Y % -29,9 10,0
D/E 0,4 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2028 3,00 €
2,87 € – 3,14 €
2,6 B 1
FY2027 1,62 €
1,54 € – 1,69 €
1,8 B 1
FY2026 0,98 €
0,93 € – 1,02 €
1,5 B 1

Points Clés

Revenue declined -29,86% annually over 5 years
ROE of 0,53% is below average
Debt/Equity of 0,41 — conservative balance sheet
Negative free cash flow of -626,43M
P/E of 49,66 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55,98%

Croissance

Revenue Growth (5Y)
-29,86%
Revenue (1Y)26,12%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
0,53%
ROIC0,25%
Net Margin2,61%
Op. Margin2,24%

Sécurité

Debt / Equity
0,41
Current Ratio2,42
Interest Coverage0,00

Valorisation

P/E Ratio
49,66
P/B Ratio0,27
EV/EBITDA77,49
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 26,12% Revenue Growth (3Y) 73,61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -29,86% Earnings Growth (5Y) -65,49%
Profitability
Revenue (TTM) 1,04B Net Income (TTM) 27,15M
ROE 0,53% ROA 0,34%
Gross Margin 0,00% Operating Margin 2,24%
Net Margin 2,61% Free Cash Flow (TTM) -626,43M
ROIC 0,25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,41 Current Ratio 2,42
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 49,66 P/B Ratio 0,27
P/S Ratio 1,30 PEG Ratio -2,89
EV/EBITDA 77,49 Dividend Yield 0,00%
Market Cap 1,35B Enterprise Value 1,81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,04B 824,88M 345,18M 1,03B 4,30B
Net Income 27,15M -378,88M -1,48B -909,43M 1,91B
EPS (Diluted) 0,11 -1,53 -6,01 -3,69 7,74
Gross Profit 0,0 580,45M -876,02M -186,61M 3,00B
Operating Income 23,30M -403,39M -2,04B -1,37B 1,94B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7,96B 9,32B 11,47B 11,87B 6,75B
Total Liabilities 3,05B 4,03B 4,22B 3,33B 677,22M
Shareholders' Equity 4,91B 5,27B 6,75B 8,00B 6,07B
Total Debt 2,01B 2,70B 2,70B 1,37B 142,54M
Cash & Equivalents 1,56B 2,05B 3,39B 5,46B 4,45B
Current Assets 4,28B 5,18B 7,73B 9,29B 5,42B
Current Liabilities 1,77B 2,59B 2,94B 2,87B 412,85M